Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus.
about
Zika Virus Pathogenesis and Tissue TropismA human antibody against Zika virus crosslinks the E protein to prevent infectionAn mRNA-based vaccine strategy against ZikaMaternal-Fetal Transmission of Zika Virus: Routes and Signals for InfectionVaccination strategies against Zika virusHumoral cross-reactivity between Zika and dengue viruses: implications for protection and pathologyRecurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.Prospects for a Zika Virus Vaccine.Animal Models of Zika Virus Infection, Pathogenesis, and Immunity.DNA vaccination protects mice against Zika virus-induced damage to the testesDelineating antibody recognition against Zika virus during natural infectionA human inferred germline antibody binds to an immunodominant epitope and neutralizes Zika virus.CD8(+) T Cell Immune Response in Immunocompetent Mice during Zika Virus Infection.Advances in Developing Therapies to Combat Zika Virus: Current Knowledge and Future PerspectivesDevelopment of Virus like Particle Vaccine and Reporter Assay for Zika Virus.Monoclonal antibodies against Zika virus: Therapeutics and their implications for vaccine design.Recent advances in understanding the adaptive immune response to Zika virus and the effect of previous flavivirus exposure.Zika Virus: What Have We Learnt Since the Start of the Recent Epidemic?Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections.Modified mRNA Vaccines Protect against Zika Virus Infection.A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential.Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III.Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.Antibody therapies for the prevention and treatment of viral infections.Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage.Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge.Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.Immune Response to Dengue and Zika.Cellular and Humoral Immunity Protect against Vaginal Zika Virus Infection in Mice.Development of Antibody Therapeutics against Flaviviruses.Humoral Immune Responses Against Zika Virus Infection and the Importance of Preexisting Flavivirus Immunity.Small-Animal Models of Zika Virus.N-glycosylation of Viral E Protein Is the Determinant for Vector Midgut Invasion by Flaviviruses.Vertical Transmission of the Zika Virus Causes Neurological Disorders in Mouse Offspring.The immunology of Zika Virus.Recombinant Zika virus envelope protein elicited protective immunity against Zika virus in immunocompetent mice.Rational Engineering and Characterization of an mAb that Neutralizes Zika Virus by Targeting a Mutationally Constrained Quaternary Epitope.Incorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E proteinEstablishment of Baculovirus-Expressed VLPs Induced Syncytial Formation Assay for Flavivirus Antiviral ScreeningHuman antibodies targeting Zika virus NS1 provide protection against disease in a mouse model
P2860
Q28733400-79F9A409-514C-41D1-91BD-D937C3F8B9DFQ28950443-548E02D9-B8C5-4E2F-B18A-1A469963BEE4Q29352285-5407390B-7033-4BB5-AB3F-59FA7C6EA9DFQ29451356-72CD0796-C16B-4AB9-A1E9-F71C3ADE777EQ29571224-4A541FDF-EB8B-4CC3-A377-B146EB536BE7Q29994510-7D36936C-EA5D-4741-A61D-8D8151D81BF5Q30145646-0799BD9D-738A-4E9F-8C5D-C5BBFC08C4DDQ30235612-9BE585B0-F7C1-44A7-856D-B70F55E3DDE3Q30238657-513BBAEB-1330-40D4-89CC-E7C2240EBB9AQ30855414-F2E77B38-4736-48F5-A3AC-2D506DC290C8Q33798068-C755A37A-1DD5-40E6-B82C-FEBCE8E0D45FQ33825684-2D03FA31-7664-4058-A7BA-72739898D6C6Q38156594-8A42BEA8-061C-4857-9CF4-7943E2426322Q38156667-9FB100C5-C882-41E9-BE05-B6EA5FCA2A4BQ38156855-CB72EB56-CDDA-460C-B1F4-36282A1DE8D7Q38157121-C2828B54-11CF-42ED-8A2A-FB0043BA4D03Q38158407-E03C0A88-45A8-46CD-B076-1C1E3BAA2BC0Q40037723-3CDE9832-999F-443A-8174-38FA00B5ED0AQ40047603-806E2250-B88B-4A04-9221-D9A1600FA969Q40049416-E2CAB0E2-BF99-4AED-BCE8-D219EC0D3FCDQ41596362-97EE0D64-8979-447F-A447-21D6945F85BCQ41919737-9C5BF1F1-9CB5-412D-8CE8-7B84C81D0E03Q41929032-7D23BE49-8D81-4A6D-AC92-B1BA8E2A7F29Q47143843-44E1FC08-A935-48E0-94DE-5BC6C557486EQ47202176-529AE09E-8269-4A42-86E6-21BEDB709196Q47263584-25C74921-D2E4-4191-9EEB-2FA71A42C9A7Q47548101-5C224660-C3FA-4AF5-BD1C-BF5315F9674CQ47551925-6A0D210E-EF6C-435F-8CD1-22121A906421Q47552139-E9F39108-E57B-4DAF-8D21-D9859BC4D357Q47558158-A34ECF22-2EAE-4600-BF51-ADC6F4706183Q47558315-4EB8B522-FC2C-4280-922D-A9BD7F868C3EQ47558337-66A8AC78-6344-4F35-973F-8780AFBCAE6FQ49791115-68793475-FA55-42B3-8E78-09B05C6B927FQ50351020-36BC397E-B95D-4C28-A520-B9EF952B0883Q51336389-C5CA2B7C-DC83-4FA1-9067-47A42CB2B740Q51782806-7416165E-2131-4A9F-8192-184266149FE2Q54215484-18962A4E-E8E2-48D2-84A8-8560D7F89EFFQ56000963-12CCF135-A123-4197-92F1-0A684A1DC9C2Q56347959-B0BAC67F-7445-4235-A5AF-C8321B8F861FQ58569620-3C42397F-5F33-4017-816A-5A6A5DF78659
P2860
Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Molecular determinants of huma ...... ient infected with Zika virus.
@en
type
label
Molecular determinants of huma ...... ient infected with Zika virus.
@en
prefLabel
Molecular determinants of huma ...... ient infected with Zika virus.
@en
P2093
P2860
P50
P921
P1476
Molecular determinants of huma ...... ient infected with Zika virus.
@en
P2093
Huabing Yang
Jianhua He
Jianhua Li
Jianping Yang
Jianxun Qi
Jianying Liu
Jinghua Yan
P2860
P304
P356
10.1126/SCITRANSLMED.AAI8336
P407
P50
P577
2016-12-01T00:00:00Z